Deadly brain tumors show vulnerability to new sound wave approach
In a promising sign for the potential of focused sound waves to improve care for brain tumors, UVA Health researchers have determined that tumors called gliomas may be even more receptive to targeted drug delivery than normal brain tissue.
A recent study carried out by researchers at the University of Virginia Health has unveiled a potential breakthrough in the treatment of brain tumors, specifically gliomas, with the application of focused ultrasound technology. This innovative approach could significantly enhance the effectiveness of drug delivery to brain tumors, a challenge that has historically hindered treatment success due to the brain's protective barrier, known as the blood-brain barrier.
The team, led by Dr. Richard J. Price, utilized advanced MRI techniques to measure drug delivery in real-time, allowing for unprecedented resolution. This development has dispelled previous concerns that brain tumors might be inherently resistant to targeted drug delivery via focused ultrasound. Instead, the results suggest that gliomas, the most common primary brain tumors in adults, may be more receptive to this treatment method compared to normal brain tissue.
The research indicates that the success of drug delivery through focused ultrasound in brain tumors is not diminished but potentially enhanced, particularly for certain types of therapeutics. This is particularly significant given that glioblastomas, the deadliest form of brain cancer, have a poor prognosis with most patients succumbing within 5-10 years of diagnosis.
Furthermore, the study identified an optimal size range for drug molecules that, when delivered via focused ultrasound, showed the best effectiveness in reaching and attacking tumor cells. The study found that smaller molecules were less efficient, while larger molecules were less effective than medium-sized ones. This "Goldilocks" size range could guide the development of future drug formulations for this novel treatment approach.
The implications of this research are far-reaching, potentially revolutionizing the treatment of brain tumors. With the addition of a cutting-edge MRI-guided focused ultrasound system to UVA Health's research tools, the Focused Ultrasound Cancer Immunotherapy Center is well-positioned to accelerate the delivery of promising therapies to patients.
This system will enable researchers to both deliver treatment and closely monitor its effects, providing a more detailed understanding of how to optimize drug delivery for brain tumors.
While more research is needed to further validate these findings, the results are promising and could pave the way for new treatment options for patients with brain cancers. The collaboration between UVA Cancer Center, UVA's Paul and Diane Manning Institute of Biotechnology, and the Manning Institute aims to fast-track new treatments and cures for the most challenging diseases, including brain tumors.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
